Sam Brusco, Associate Editor05.16.22
Medtronic earned U.S. Food and Drug Administration (FDA) approval for its Onyx Frontier drug-eluting stent (DES), the latest evolution in the company’s Resolute DES family. The new DES features an enhanced delivery system meant to boost deliverability and acute performance in challenging cases.
Onyx Frontier DES helps treat coronary artery disease (CAD) patients. To help restore blood flow in blocked coronary arteries, the stent can be delivered in a minimally invasive procedure to prop open the artery.
"The new Onyx Frontier DES, with its enhanced deliverability, will continue to help interventional cardiologists treat complex coronary cases and larger ranges of vessel sizes more efficiently," Azeem Latib, MD, section head of interventional cardiology and medical director of structural heart interventions at Montefiore Medical Center told the press. "Delivering safe and effective outcomes to our patients is our number one priority. It's important that physicians have access to tools like the Onyx Frontier DES that can allow them to efficiently achieve those outcomes."
Design changes include more catheter flexibility, dual-layer balloon tech, and a lower crossing profile. Onyx Frontier also has a broad size matrix to treat more patients, and according to the company is the only 2 mm DES available in the U.S.
"The Onyx Frontier DES FDA approval is a very important milestone for Medtronic's Coronary business and demonstrates our commitment to interventional cardiologists by providing best-in-class products," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business. "The Onyx Frontier launch also correlates directly to Medtronic's commitment to engineering. The team built upon the design and clinical successes of the Resolute Onyx DES and has continued to evolve proven DES technology to further address the needs of physicians. We look forward to continuing the pursuit of innovation each day."
Onyx Frontier DES helps treat coronary artery disease (CAD) patients. To help restore blood flow in blocked coronary arteries, the stent can be delivered in a minimally invasive procedure to prop open the artery.
"The new Onyx Frontier DES, with its enhanced deliverability, will continue to help interventional cardiologists treat complex coronary cases and larger ranges of vessel sizes more efficiently," Azeem Latib, MD, section head of interventional cardiology and medical director of structural heart interventions at Montefiore Medical Center told the press. "Delivering safe and effective outcomes to our patients is our number one priority. It's important that physicians have access to tools like the Onyx Frontier DES that can allow them to efficiently achieve those outcomes."
Design changes include more catheter flexibility, dual-layer balloon tech, and a lower crossing profile. Onyx Frontier also has a broad size matrix to treat more patients, and according to the company is the only 2 mm DES available in the U.S.
"The Onyx Frontier DES FDA approval is a very important milestone for Medtronic's Coronary business and demonstrates our commitment to interventional cardiologists by providing best-in-class products," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business. "The Onyx Frontier launch also correlates directly to Medtronic's commitment to engineering. The team built upon the design and clinical successes of the Resolute Onyx DES and has continued to evolve proven DES technology to further address the needs of physicians. We look forward to continuing the pursuit of innovation each day."